Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 12, 2016, Pages 7396-7401

  Ito, Akinobu ^a   Nishikawa, Toru ^a   Matsumoto, Shuhei ^a   Yoshizawa, Hidenori ^a   Sato, Takafumi ^a   Nakamura, Rio ^a   Tsuji, Masakatsu ^a   Yamano, Yoshinori ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBON 14; CATECHOL DERIVATIVE; CEFIDEROCOL; CEFIDEROCOL CATECHOL 3 METHOXY; CEFTAZIDIME; FERRIC ION; THIAZOLE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CALCEIN AM; CARBON; CEPHALOSPORIN DERIVATIVE; FLUORESCEIN DERIVATIVE; FLUORESCENT DYE; IRON; IRON CHELATING AGENT; S-649266; THIAZOLE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; CELL LEVEL; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; IN VITRO STUDY; IRON CHELATION; IRON DEPLETION; IRON TRANSPORT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; CHEMISTRY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION; TRANSPORT AT THE CELLULAR LEVEL;

ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; CARBON RADIOISOTOPES; CEFTAZIDIME; CEPHALOSPORINS; FLUORESCEINS; FLUORESCENT DYES; IRON; IRON CHELATING AGENTS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 84996478385     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01405-16     Document Type: Article

References (37)

1. Denis O, Nonhoff C, Dowzicky MJ. 2014. Antimicrobial susceptibility among Gram-positive and Gram-negative isolates collected in Europe between 2004 and 2010. J Glob Antimicrob Resist 2:155-161. http://dx.doi.org/10.1016/j.jgar.2014.05.001.
2. Kanj SS, Whitelaw A, Dowzicky MJ. 2014. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011. Int J Antimicrob Agents 43:170-178. http://dx.doi.org/10.1016/j.ijantimicag.2013.10.011.
3. Woodford N, Turton JF, Livermore DM. 2011. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 35:736-755. http://dx.doi.org/10.1111/j.1574-6976.2011.00268.x.
4. Bonomo RA, Szabo D. 2006. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 43:S49-S56. http://dx.doi.org/10.1086/504477.
5. Farra A, Islam S, Strålfors A, Sörberg M, Wretlind B. 2008. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem. Int J Antimicrob Agents 31:427-433. http://dx.doi.org/10.1016/j.ijantimicag.2007.12.016.
6. Gupta V. 2008. Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opin Investig Drugs 17:131-143. http://dx.doi.org/10.1517/13543784.17.2.131.
7. Livermore DM. 2012. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med 27:128-142. http://dx.doi.org/10.3904/kjim.2012.27.2.128.
8. Livermore DM. 2001. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 47:247-250. http://dx.doi.org/10.1093/jac/47.3.247.
9. Okamoto K, Gotoh N, Nishino T. 2002. Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa. Antimicrob Agents Chemother 46:2696-2699. http://dx.doi.org/10.1128/AAC.46.8.2696-2699.2002.
10. Strateva T, Yordanov D. 2009. Pseudomonas aeruginosa: a phenomenon of bacterial resistance. J Med Microbiol 58:1133-1148. http://dx.doi.org/10.1099/jmm.0.009142-0.
11. Walsh TR, Toleman MA, Poirel L, Nordmann P. 2005. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 18:306-325. http://dx.doi.org/10.1128/CMR.18.2.306-325.2005.
12. Jovcic B, Lepsanovic Z, Suljagic V, Rackov G, Vegovic J, Topisirovic L, Kojic M. 2011. Emergence of NDM-1 metallo-β-lactamase in Pseudomonas aeruginosa clinical isolates from Serbia. Antimicrob Agents Chemother 55:3929-3931. http://dx.doi.org/10.1128/AAC.00226-11.
13. Patel G, Bonomo RA. 2013. "Stormy waters ahead": global emergence of carbapenemases. Front Microbiol 4:48. http://dx.doi.org/10.3389/fmicb.2013.00048.
14. Drechsel H, Winkelmann G. 1997. Iron chelation and siderophores, p 1-49. In Winkelmann G, Carrano CJ (ed), Transition metals in microbial metabolism. Harwood Academic, Amsterdam, Netherlands.
15. Griffiths E. 1978. Iron in biological systems, p 1-27. In Bullen JJ, Griffiths E (ed), Iron and infection. John Wiley & Sons, New York, NY.
16. Wienk KJ, Marx JJ, Beynen AC. 1999. The concept of iron bioavailability and its assessment. Eur J Nutr 38:51-75. http://dx.doi.org/10.1007/s003940050046.
17. Cornelis P, Matthijs S, van Oeffelen L. 2009. Iron uptake regulation in Pseudomonas aeruginosa. Biometals 22:15-22. http://dx.doi.org/10.1007/s10534-008-9193-0.
18. Mollmann U, Heinisch L, Bauernfeind A, Kohler T, Ankel-Fuchs D. 2009. Siderophores as drug delivery agents: application of the "Trojan Horse" strategy. Biometals 22:615-624. http://dx.doi.org/10.1007/s10534-009-9219-2.
19. Page MG, Dantier C, Desarbre E. 2010. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli. Antimicrob Agents Chemother 54:2291-2302. http://dx.doi.org/10.1128/AAC.01525-09.
20. Foley T, Simeonov A. 2012. Targeting iron assimilation to develop new antibacterials. Expert Opin Drug Discov 7:831-847. http://dx.doi.org/10.1517/17460441.2012.708335.
21. Kim A, Kutschke A, Ehmann DE, Patey SA, Crandon J, Gorseth E, Miller AA, McLaughlin RE, Blinn CM, Chen A, Nayar AS, Dangel B, Tsai AS, Rooney MT, Murphy-Benenato KE, Eakin AE, Nicolau DP. 2015. Pharmacodynamic profiling of a siderophore-conjugated monocarbam in Pseudomonas aeruginosa: assessing the risk for resistance and attenuated efficacy. Antimicrob Agents Chemother 59:7743-7752. http://dx.doi.org/10.1128/AAC.00831-15.
22. Tomaras AP, Crandon JL, McPherson CJ, Banevicius MA, Finegan SM, Irvine RL, Brown MF, O'Donnell JP, Nicolau DP. 2013. Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa. Antimicrob Agents Chemother 57:4197-4207. http://dx.doi.org/10.1128/AAC.00629-13.
23. Tomaras AP, Crandon JL, McPherson CJ, Nicolau DP. 2015. Potentiation of antibacterial activity of the MB-1 siderophore-monobactam conjugate using an efflux pump inhibitor. Antimicrob Agents Chemother 59:2439-2442. http://dx.doi.org/10.1128/AAC.04172-14.
24. Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of S-649266, a catechol substituted siderophore cephalosporin, when tested against non-fermenting gram-negative bacteria. J Antimicrob Chemother 71:670-677. http://dx.doi.org/10.1093/jac/dkv402.
25. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of siderophore cephalosporin S-649266 against Enterobacteriaceae clinical isolates including carbapenem-resistant strains. Antimicrob Agents Chemother 60:729-734. http://dx.doi.org/10.1128/AAC.01695-15.
26. Nakamura R, Toba S, Tsuji M, Yamano Y, Shimada J. 2014. S-649266, a novel siderophore cephalosporin. IV: in vivo efficacy in various murine infection models, abstr F1-1558. Abstr 54th Intersci Conf Antimicrob Agents Chemother, American Society for Microbiology, Washington, DC.
27. Nakamura R, Toba S, Ito A, Tsuji M, Yamano Y, Shimada J. 2014. S-649266, a novel siderophore cephalosporin. V: pharmacodynamic assessment in murine thigh infection models, abstr F1-1559. Abstr 54th Intersci Conf Antimicrob Agents Chemother, American Society for Microbiology, Washington, DC.
28. Ito-Horiyama T, Ishii Y, Ito A, Sato T, Nakamura R, Fukuhara N, Tsuji M, Yamano Y, Yamaguchi K, Tateda K. 2016. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 60:4384-4386. http://dx.doi.org/10.1128/AAC.03098-15.
29. Jacobs MA, Alwood A, Thaipisuttikul I, Spencer D, Haugen E, Ernst S, Will O, Kaul R, Raymond C, Levy R, Chun-Rong L, Guenthner D, Bovee D, Olson MB, Manoil C. 2003. Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 100:14339-14344. http://dx.doi.org/10.1073/pnas.2036282100.
30. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. Document M7-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
31. Garcic A. 1979. A highly sensitive, simple determination of serum iron using chromazurol B. Clin Chim Acta 94:115-119. http://dx.doi.org/10.1016/0009-8981(79)90003-2.
32. Müller C, Hofer B, Desarbre E, Page MGP. 2010. Enhanced activity of the siderophore monosulfactam BAL30072 (BAL) against Acinetobacter in iron-limited conditions, abstr F1-2133. Abstr 50th Intersci Conf Antimicrob Agents Chemother, American Society for Microbiology, Washington, DC.
33. Vogel HJ, Bonner DM. 1956. Acetylornithinase of Escherichia coli: partial purification and some properties. J Biol Chem 218:97-106.
34. Curtis NA, Eisenstadt RL, East SJ, Cornford RJ, Walker LA, White AJ. 1988. Iron-regulated outer membrane proteins of Escherichia coli K-12 and mechanism of action of catechol-substituted cephalosporins. Antimicrob Agents Chemother 32:1879-1886. http://dx.doi.org/10.1128/AAC.32.12.1879.
35. Gensberg K, Doyle EJ, Perry DJ, Smith AW. 1994. Uptake of BRL 41897A, a C(7) alpha-formamido substituted cephalosporin, via the ferripyochelin transport system of Pseudomonas aeruginosa. J Antimicrob Chemother 34:697-705. http://dx.doi.org/10.1093/jac/34.5.697.
36. van Delden C, Page MG, Kohler T. 2013. Involvement of Fe uptake systems and AmpC β-lactamase in susceptibility to the siderophore monosulfactam BAL30072 in Pseudomonas aeruginosa. Antimicrob Agents Chemother 57:2095-2102. http://dx.doi.org/10.1128/AAC.02474-12.
37. McPherson CJ, Aschenbrenner LM, Lacey BM, Fahnoe KC, Lemmon MM, Finegan SM, Tadakamalla B, O'Donnell JP, Mueller JP, Tomaras AP. 2012. Clinically relevant Gram-negative resistance mechanisms have no effect on the efficacy of MC-1, a novel siderophore-conjugated monocarbam. Antimicrob Agents Chemother 56:6334-6342. http://dx.doi.org/10.1128/AAC.01345-12.